search
Back to results

Phase 1 Study of SAR440894 vs Placebo

Primary Purpose

Chikungunya Virus Infection

Status
Recruiting
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Placebo
SAR440894
Sponsored by
National Institute of Allergy and Infectious Diseases (NIAID)
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Chikungunya Virus Infection focused on measuring Chikungunya Virus, dose escalation, healthy adults, Immunogenicity, Pharmacokinetics, phase 1, placebo, SAR440894

Eligibility Criteria

18 Years - 45 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Must be a healthy adult 18 to 45 years of age, inclusive, with a body mass index (BMI) greater than 18 or less than 35 kg/m^2, inclusive.
  2. Participants of childbearing potential* having vaginal intercourse must use an effective method of contraception** from 30 days before study product administration through the final study visit.

    *Not sterilized via hysterectomy or bilateral oophorectomy and/or salpingectomy or be less than 1 year from the last menses if menopausal.

    **Includes any of the following (a) exclusive non-male sexual relationships; (b) monogamous relationship with vasectomized partner (greater than or equal to 180 days between procedure and subject receipt of investigational product); (c) bilateral tubal ligation or tubal occlusion (Essure(R)) with documented radiographic confirmation at 90 days; (d) effective intrauterine device (IUD); (e) hormonal implants (Implanon(R)); (f) other hormonal contraceptives (such as birth control pills, vaginal rings, patches or injections); (g) barrier methods (condom, diaphragm, cervical cap) PLUS spermicide (gel or foam)

  3. Women of childbearing potential must agree not to donate ova or oocytes (ie, human eggs) during the study.
  4. Male subjects (including those with vasectomies) whose partners are of childbearing potential should use condoms with spermicide and not donate sperm for the duration of the study.
  5. Must have adequate venous access for IV infusions and blood draws.
  6. Agrees to be available for all study visits and willing to cooperate fully with the requirements* of the study protocol.

    *Requirements include remaining in confinement for at least 72 hours after receiving study product and other activities outlined in the protocol's Schedule of Events.

  7. Is able to understand the informed consent process and procedures and signs the consent form.
  8. Will agree not to donate any blood or blood products* for the duration of the study.

    • Includes whole blood, red blood cells, platelets, plasma, or plasma derivatives.
  9. Will agree to avoid travel to endemic areas (as defined by the Center for Disease Control (CDC)) for Chikungunya virus at any point during the follow-up period. https://www.cdc.gov/chikungunya/geo/index.html

Exclusion Criteria:

  1. Has any medical condition (e.g., renal dysfunction) that, in the opinion of the site PI or appropriate sub-investigator listed on Food and Drug Administration (FDA) Form 1572, is a contraindication to study participation.
  2. Has any clinically significant (CS) electrocardiogram (ECG) abnormalities in the opinion of the site Principal Investigator (PI) or appropriate sub-investigator been listed on FDA Form 1572?
  3. Use of any prohibited prescription medication (excluding contraceptives in females) within 14 days before study product administration, through Day 56* *Prohibited medications include immunosuppressives; immune modulators; oral corticosteroids (topical/intranasal steroids are acceptable); prescription Non-Steroidal Anti-inflammatory Drugs (NSAIDs); anti-neoplastic agents; any vaccine (licensed or investigational). If study activities overlap with the influenza season, subjects will be instructed to obtain influenza vaccine at least 30 days prior to proposed dosing or delay vaccination until after Day 56. Subjects will be instructed to obtain the last dose of any vaccine for SARS-CoV-2 (COVID-19) at least 30 days prior to proposed dosing or delay vaccination until after Day 56.
  4. Use of nonprescription systemic drugs within 7 days before study product administration (includes vitamins, antacids*, over-the-counter drugs**, herbal/dietary supplements, etc.) through Day 28***

    *Nonprescription drugs and supplements may be allowed before Day 28 at the discretion of the site PI.

    **Includes proton pump inhibitors and H2-blockers (Histamine-2 blockers)

    ***Nonprescription drugs and supplements may be allowed before Day 28 at the discretion of the site PI.

  5. Hypertension, with confirmed systolic blood pressure (BP) greater than 140 mm Hg or confirmed diastolic BP greater than 90 mm Hg, measured after 5 minutes of rest at screening.
  6. Hypotension, with confirmed systolic BP less than 90 mm Hg.
  7. Resting heart rate (HR) less than 45 bpm or greater than 100 bpm at screening.
  8. Body weight less than 50 kg.
  9. History of a significant illness, per the investigators' clinical judgment, within 2 weeks before dosing (subjects can screen after illness is resolved for 2 weeks).
  10. Known diagnosis of prolonged QT interval, congenital long QT syndrome, bradyarrhythmias, or uncompensated heart failure.
  11. Males with a median QTcF greater than 450 msec or females with a median QTcF greater than 460 msec (Fridericia's correction) at Screening.* *ECG tracings should be recorded at least 1 minute apart, after at least 5 minutes of rest in the supine position. If the median QTcF value from the 3 tracings exceeds the limits stated, the subject is disqualified.
  12. Any history of malignancy ever, except low-grade skin cancer (ie, basal cell carcinoma thought to be cured).
  13. History of drug abuse, alcohol abuse, or significant psychiatric history according to the investigators' judgment within 12 months before Screening.
  14. Positive screen for hepatitis B virus surface antigen, hepatitis C virus antibody, or human immunodeficiency virus (HIV) antibody.
  15. Excessive consumption of beverages containing xanthine bases, or more than 400 mg of caffeine per day within 1 week of study product administration through the final study visit.
  16. Consumption of alcohol within 24 hours before study product administration.
  17. Use of nicotine-containing products within 30 days before study product administration through the final study visit.
  18. Positive drug screen*, positive cotinine screen, or positive breathalyzer test for alcohol at Screening or admission (Day -1).

    *Cannabinoids, amphetamines, barbiturates, cocaine, opiates, benzodiazepines and phencyclidine. Subjects should be notified by phone not to consume any poppy seeds within 24 hours before the screening urine test to avoid a false positive opioid test result.

  19. If female, serum positive pregnancy test at Screening or serum positive pregnancy test on Day -1.
  20. Breastfeeding throughout the duration of the study
  21. Total WBC and platelet counts, hemoglobin*, total bilirubin*, alanine/aspartate aminotransferase and sodium* are Grade 1 or higher** at Screening visit.

    *For sodium; lower limit values of 133-134 mmol/L will be allowed at Screening and Day -1/baseline. If the result at screening is 132 mmol/L or below , the participant will be scheduled to repeat the test during the screening period but before Day-1 to assure that it is at or > 133 mmol/L Repeated sodium values of 132 mmol/L and below are exclusionary. Potential subjects excluded prior to Protocol Version 6.0 with Grade 1 sodium values may be rescreened.

    For hemoglobin; a lower limit of 13.5 g/dL for males and 11.5 mg/dL for females is allowable at Screening. Hemoglobin values of 13.4 mg/dL and below for males and 11.4 mg/dL and below for females are exclusionary at Screening.

    For total bilirubin; upper limit values of 1.2 mg/dL will be allowed at Screening and Day -1/baseline provided the AST and ALT are within normal limits. Total bilirubin values of 1.3mg/dL and above are exclusionary. Potential subjects excluded prior to Protocol Version 6.0 with bilirubin values below the Version 6.0 upper limit may be rescreened.

    **Grade 1 or higher toxicity, see Appendix C or Appendix D. Safety laboratory tests drawn on Day -1 or Screening if within 48 hours of planned dosing will serve as baseline values. Day -1 laboratory tests with a Grade 1 severity, other than those noted above, will not exclude subjects from participation.

  22. Potassium, bicarbonate or creatinine results are Grade 1 or higher at either Screening or Day -1/Baseline visits.
  23. Received an experimental agent (vaccine, drug, biologic, device, or medication) within 30 days or 5 half-lives (whichever is longer) before study product administration.*

    *Prior participation at any time in noninvasive methodology trials in which no drugs were given is acceptable.

  24. Is participating in or plans to participate in another clinical trial with an interventional agent that will be received during this trial.
  25. Has donated more than 500 mL of blood or blood products* within the month before Screening.

    *Includes whole blood, red blood cells, platelets, plasma, or plasma derivatives.

  26. Has a history of serologically-proven Chikungunya virus (CHIKV) exposure at any point, or positive anti CHIKV antibodies at Screening.
  27. Has received blood products within 120 days prior to Screening.
  28. Has received any mAb in the past, whether licensed or investigational, or plans to receive a mAb during the study.

Sites / Locations

  • Johnson County Clin-Trials (JCCT)
  • Duke University School of Medicine - Duke Clinical Research Institute - Duke Clinical Research UnitRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm Type

Experimental

Experimental

Experimental

Experimental

Experimental

Arm Label

Cohort 1

Cohort 2

Cohort 3

Cohort 4

Cohort 5

Arm Description

0.3 mg/kg of SAR440894 (n=6) or placebo (n=2) administered once during a 60-minute intravenous (IV) infusion. 2 sentinel subjects will receive dosing for review of safety data (SAR440894 n=1, placebo n=1) before remainder of cohort.

1 mg/kg of SAR440894 (n=6) or placebo (n=2) administered once during a 60-minute intravenous (IV) infusion. 2 sentinel subjects will receive dosing for review of safety data (SAR440894 n=1, placebo n=1) before remainder of cohort.

3 mg/kg of SAR440894 (n=6) or placebo (n=2) administered once during a 60-minute intravenous (IV) infusion. 2 sentinel subjects will receive dosing for review of safety data (SAR440894 n=1, placebo n=1) before remainder of cohort.

10 mg/kg of SAR440894 (n=6) or placebo (n=2) administered once during a 60-minute intravenous (IV) infusion. 2 sentinel subjects will receive dosing for review of safety data (SAR440894 n=1, placebo n=1) before remainder of cohort.

20 mg/kg of SAR440894 (n=6) or placebo (n=2) administered once during a 60-minute intravenous (IV) infusion. 2 sentinel subjects will receive dosing for review of safety data (SAR440894 n=1, placebo n=1) before remainder of cohort.

Outcomes

Primary Outcome Measures

Occurrence of adverse events (AEs)
Occurrence of changes from baseline in clinical safety laboratory values
Clinical safety laboratory evaluations include hematology, chemistry, urinalysis, and coagulation.
Occurrence of changes from baseline in vital signs
Vitals signs include temperature, heart rate, blood pressure, and respiratory rate.
Occurrence of clinically significant changes in ECG parameters from baseline
Significant changes are defined as the following: Any significant change in rate or rhythm as determined by the site PI, QTcF interval of greater than 450 ms (male) or greater than 460 ms (female), Increase from the QTcF baseline (defined as median of pre-dose measurements) greater than 50 ms until the change resolves.
Occurrence of serious adverse events (SAEs)

Secondary Outcome Measures

Changes in concentration of SAR440894 plasma human anti-drug antibody (ADA)
Will be used to determine immunogenicity of SAR440894.
Presence/absence of SAR440894 plasma human anti-drug antibody (ADA)
Will be used to determine immunogenicity of SAR440894.
SAR440894 plasma concentration
Plasma concentration will be determined by using a validated enzyme-linked immunosorbent assay. Plasma concentrations will be used to determine plasma PK of SAR440894.

Full Information

First Posted
June 19, 2020
Last Updated
July 20, 2023
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
search

1. Study Identification

Unique Protocol Identification Number
NCT04441905
Brief Title
Phase 1 Study of SAR440894 vs Placebo
Official Title
A Phase 1, Randomized, Double-Blind, Single Center, Single Dose Escalation Study to Evaluate the Safety, Pharmacokinetics, and Immunogenicity of SAR440894 vs Placebo in Healthy Adults
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Recruiting
Study Start Date
October 14, 2020 (Actual)
Primary Completion Date
December 1, 2023 (Anticipated)
Study Completion Date
December 1, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No

5. Study Description

Brief Summary
A single, ascending-dose design with five dose-cohorts of 8 subjects. Forty healthy adults aged 18 to 45, inclusive, will be recruited and admitted at one US site. Each subject will be randomized to receive either SAR440894 or matching placebo via 60-minute intravenous infusion. In each cohort of 8 subjects, the randomization ratio will be 6 active to 2 placebo, and 2 sentinel subjects (one from each active and placebo group) will be dosed first. Dosing of the next dose-cohort will be dependent on acceptable meeting predefined safety criteria in the preceding cohort. Each subject's participation will take place over approximately 150 days, not including the screening visit. There are no hypotheses for this phase I study. The primary objective will be to determine the safety of single ascending intravenous (IV) infusions of SAR440894 when administered in healthy adults.
Detailed Description
A single, ascending-dose design with five dose-cohorts of 8 subjects. Forty healthy adults aged 18 to 45, inclusive, will be recruited and admitted at one US site. Each subject will be randomized to receive either SAR440894 or matching placebo via 60-minute intravenous infusion. In each cohort of 8 subjects, the randomization ratio will be 6 active to 2 placebo, and 2 sentinel subjects (one from each active and placebo group) will be dosed first. Dosing of the next dose-cohort will be dependent on acceptable meeting predefined safety criteria in the preceding cohort. Each subject's participation will take place over approximately 150 days, not including the screening visit. There are no hypotheses for this phase I study. The primary objective will be to determine the safety of single ascending intravenous (IV) infusions of SAR440894 when administered in healthy adults. The secondary objectives are: 1) to determine the pharmacokinetics (PK) of single ascending doses of 60-minute IV infusions SAR440894 in healthy adults and 2) to asses the immunogenicity of single ascending doses of 60-minute IV infusions SAR440894 in healthy adults.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Chikungunya Virus Infection
Keywords
Chikungunya Virus, dose escalation, healthy adults, Immunogenicity, Pharmacokinetics, phase 1, placebo, SAR440894

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
40 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Cohort 1
Arm Type
Experimental
Arm Description
0.3 mg/kg of SAR440894 (n=6) or placebo (n=2) administered once during a 60-minute intravenous (IV) infusion. 2 sentinel subjects will receive dosing for review of safety data (SAR440894 n=1, placebo n=1) before remainder of cohort.
Arm Title
Cohort 2
Arm Type
Experimental
Arm Description
1 mg/kg of SAR440894 (n=6) or placebo (n=2) administered once during a 60-minute intravenous (IV) infusion. 2 sentinel subjects will receive dosing for review of safety data (SAR440894 n=1, placebo n=1) before remainder of cohort.
Arm Title
Cohort 3
Arm Type
Experimental
Arm Description
3 mg/kg of SAR440894 (n=6) or placebo (n=2) administered once during a 60-minute intravenous (IV) infusion. 2 sentinel subjects will receive dosing for review of safety data (SAR440894 n=1, placebo n=1) before remainder of cohort.
Arm Title
Cohort 4
Arm Type
Experimental
Arm Description
10 mg/kg of SAR440894 (n=6) or placebo (n=2) administered once during a 60-minute intravenous (IV) infusion. 2 sentinel subjects will receive dosing for review of safety data (SAR440894 n=1, placebo n=1) before remainder of cohort.
Arm Title
Cohort 5
Arm Type
Experimental
Arm Description
20 mg/kg of SAR440894 (n=6) or placebo (n=2) administered once during a 60-minute intravenous (IV) infusion. 2 sentinel subjects will receive dosing for review of safety data (SAR440894 n=1, placebo n=1) before remainder of cohort.
Intervention Type
Other
Intervention Name(s)
Placebo
Intervention Description
One time 60-minute IV infusion of lyophilized placebo for SAR440894
Intervention Type
Biological
Intervention Name(s)
SAR440894
Intervention Description
One time 60-minute IV infusion of SAR440894 monoclonal antibody (IgG1) directed against the E2 envelope protein of chikungunya virus
Primary Outcome Measure Information:
Title
Occurrence of adverse events (AEs)
Time Frame
Day 1 through Day 150
Title
Occurrence of changes from baseline in clinical safety laboratory values
Description
Clinical safety laboratory evaluations include hematology, chemistry, urinalysis, and coagulation.
Time Frame
Day 1 through Day 150
Title
Occurrence of changes from baseline in vital signs
Description
Vitals signs include temperature, heart rate, blood pressure, and respiratory rate.
Time Frame
Day 1 through Day 150
Title
Occurrence of clinically significant changes in ECG parameters from baseline
Description
Significant changes are defined as the following: Any significant change in rate or rhythm as determined by the site PI, QTcF interval of greater than 450 ms (male) or greater than 460 ms (female), Increase from the QTcF baseline (defined as median of pre-dose measurements) greater than 50 ms until the change resolves.
Time Frame
Day 1 through Day 150
Title
Occurrence of serious adverse events (SAEs)
Time Frame
Day 1 through Day 150
Secondary Outcome Measure Information:
Title
Changes in concentration of SAR440894 plasma human anti-drug antibody (ADA)
Description
Will be used to determine immunogenicity of SAR440894.
Time Frame
Day 1 through Day 150
Title
Presence/absence of SAR440894 plasma human anti-drug antibody (ADA)
Description
Will be used to determine immunogenicity of SAR440894.
Time Frame
Day 1 through Day 150
Title
SAR440894 plasma concentration
Description
Plasma concentration will be determined by using a validated enzyme-linked immunosorbent assay. Plasma concentrations will be used to determine plasma PK of SAR440894.
Time Frame
Day 1 through Day 150

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Must be a healthy adult 18 to 45 years of age, inclusive, with a body mass index (BMI) greater than 18 or less than 35 kg/m^2, inclusive. Participants of childbearing potential* having vaginal intercourse must use an effective method of contraception** from 30 days before study product administration through the final study visit. *Not sterilized via hysterectomy or bilateral oophorectomy and/or salpingectomy or be less than 1 year from the last menses if menopausal. **Includes any of the following (a) exclusive non-male sexual relationships; (b) monogamous relationship with vasectomized partner (greater than or equal to 180 days between procedure and subject receipt of investigational product); (c) bilateral tubal ligation or tubal occlusion (Essure(R)) with documented radiographic confirmation at 90 days; (d) effective intrauterine device (IUD); (e) hormonal implants (Implanon(R)); (f) other hormonal contraceptives (such as birth control pills, vaginal rings, patches or injections); (g) barrier methods (condom, diaphragm, cervical cap) PLUS spermicide (gel or foam) Women of childbearing potential must agree not to donate ova or oocytes (ie, human eggs) during the study. Male subjects (including those with vasectomies) whose partners are of childbearing potential should use condoms with spermicide and not donate sperm for the duration of the study. Must have adequate venous access for IV infusions and blood draws. Agrees to be available for all study visits and willing to cooperate fully with the requirements* of the study protocol. *Requirements include remaining in confinement for at least 72 hours after receiving study product and other activities outlined in the protocol's Schedule of Events. Is able to understand the informed consent process and procedures and signs the consent form. Will agree not to donate any blood or blood products* for the duration of the study. Includes whole blood, red blood cells, platelets, plasma, or plasma derivatives. Will agree to avoid travel to endemic areas (as defined by the Center for Disease Control (CDC)) for Chikungunya virus at any point during the follow-up period. https://www.cdc.gov/chikungunya/geo/index.html Exclusion Criteria: Has any medical condition (e.g., renal dysfunction) that, in the opinion of the site PI or appropriate sub-investigator listed on Food and Drug Administration (FDA) Form 1572, is a contraindication to study participation. Has any clinically significant (CS) electrocardiogram (ECG) abnormalities in the opinion of the site Principal Investigator (PI) or appropriate sub-investigator been listed on FDA Form 1572? Use of any prohibited prescription medication (excluding contraceptives in females) within 14 days before study product administration, through Day 56* *Prohibited medications include immunosuppressives; immune modulators; oral corticosteroids (topical/intranasal steroids are acceptable); prescription Non-Steroidal Anti-inflammatory Drugs (NSAIDs); anti-neoplastic agents; any vaccine (licensed or investigational). If study activities overlap with the influenza season, subjects will be instructed to obtain influenza vaccine at least 30 days prior to proposed dosing or delay vaccination until after Day 56. Subjects will be instructed to obtain the last dose of any vaccine for SARS-CoV-2 (COVID-19) at least 30 days prior to proposed dosing or delay vaccination until after Day 56. Use of nonprescription systemic drugs within 7 days before study product administration (includes vitamins, antacids*, over-the-counter drugs**, herbal/dietary supplements, etc.) through Day 28*** *Nonprescription drugs and supplements may be allowed before Day 28 at the discretion of the site PI. **Includes proton pump inhibitors and H2-blockers (Histamine-2 blockers) ***Nonprescription drugs and supplements may be allowed before Day 28 at the discretion of the site PI. Hypertension, with confirmed systolic blood pressure (BP) greater than 140 mm Hg or confirmed diastolic BP greater than 90 mm Hg, measured after 5 minutes of rest at screening. Hypotension, with confirmed systolic BP less than 90 mm Hg. Resting heart rate (HR) less than 45 bpm or greater than 100 bpm at screening. Body weight less than 50 kg. History of a significant illness, per the investigators' clinical judgment, within 2 weeks before dosing (subjects can screen after illness is resolved for 2 weeks). Known diagnosis of prolonged QT interval, congenital long QT syndrome, bradyarrhythmias, or uncompensated heart failure. Males with a median QTcF greater than 450 msec or females with a median QTcF greater than 460 msec (Fridericia's correction) at Screening.* *ECG tracings should be recorded at least 1 minute apart, after at least 5 minutes of rest in the supine position. If the median QTcF value from the 3 tracings exceeds the limits stated, the subject is disqualified. Any history of malignancy ever, except low-grade skin cancer (ie, basal cell carcinoma thought to be cured). History of drug abuse, alcohol abuse, or significant psychiatric history according to the investigators' judgment within 12 months before Screening. Positive screen for hepatitis B virus surface antigen, hepatitis C virus antibody, or human immunodeficiency virus (HIV) antibody. Excessive consumption of beverages containing xanthine bases, or more than 400 mg of caffeine per day within 1 week of study product administration through the final study visit. Consumption of alcohol within 24 hours before study product administration. Use of nicotine-containing products within 30 days before study product administration through the final study visit. Positive drug screen*, positive cotinine screen, or positive breathalyzer test for alcohol at Screening or admission (Day -1). *Cannabinoids, amphetamines, barbiturates, cocaine, opiates, benzodiazepines and phencyclidine. Subjects should be notified by phone not to consume any poppy seeds within 24 hours before the screening urine test to avoid a false positive opioid test result. If female, serum positive pregnancy test at Screening or serum positive pregnancy test on Day -1. Breastfeeding throughout the duration of the study Total WBC and platelet counts, hemoglobin*, total bilirubin*, alanine/aspartate aminotransferase and sodium* are Grade 1 or higher** at Screening visit. *For sodium; lower limit values of 133-134 mmol/L will be allowed at Screening and Day -1/baseline. If the result at screening is 132 mmol/L or below , the participant will be scheduled to repeat the test during the screening period but before Day-1 to assure that it is at or > 133 mmol/L Repeated sodium values of 132 mmol/L and below are exclusionary. Potential subjects excluded prior to Protocol Version 6.0 with Grade 1 sodium values may be rescreened. For hemoglobin; a lower limit of 13.5 g/dL for males and 11.5 mg/dL for females is allowable at Screening. Hemoglobin values of 13.4 mg/dL and below for males and 11.4 mg/dL and below for females are exclusionary at Screening. For total bilirubin; upper limit values of 1.2 mg/dL will be allowed at Screening and Day -1/baseline provided the AST and ALT are within normal limits. Total bilirubin values of 1.3mg/dL and above are exclusionary. Potential subjects excluded prior to Protocol Version 6.0 with bilirubin values below the Version 6.0 upper limit may be rescreened. **Grade 1 or higher toxicity, see Appendix C or Appendix D. Safety laboratory tests drawn on Day -1 or Screening if within 48 hours of planned dosing will serve as baseline values. Day -1 laboratory tests with a Grade 1 severity, other than those noted above, will not exclude subjects from participation. Potassium, bicarbonate or creatinine results are Grade 1 or higher at either Screening or Day -1/Baseline visits. Received an experimental agent (vaccine, drug, biologic, device, or medication) within 30 days or 5 half-lives (whichever is longer) before study product administration.* *Prior participation at any time in noninvasive methodology trials in which no drugs were given is acceptable. Is participating in or plans to participate in another clinical trial with an interventional agent that will be received during this trial. Has donated more than 500 mL of blood or blood products* within the month before Screening. *Includes whole blood, red blood cells, platelets, plasma, or plasma derivatives. Has a history of serologically-proven Chikungunya virus (CHIKV) exposure at any point, or positive anti CHIKV antibodies at Screening. Has received blood products within 120 days prior to Screening. Has received any mAb in the past, whether licensed or investigational, or plans to receive a mAb during the study.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Michael Cohen-Wolkowiez
Phone
19196688812
Email
michael.cohenwolkowiez@duke.edu
Facility Information:
Facility Name
Johnson County Clin-Trials (JCCT)
City
Lenexa
State/Province
Kansas
ZIP/Postal Code
66219
Country
United States
Individual Site Status
Not yet recruiting
Facility Name
Duke University School of Medicine - Duke Clinical Research Institute - Duke Clinical Research Unit
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27710
Country
United States
Individual Site Status
Recruiting

12. IPD Sharing Statement

Learn more about this trial

Phase 1 Study of SAR440894 vs Placebo

We'll reach out to this number within 24 hrs